Compounded semaglutide has made GLP-1 therapy financially accessible for millions of patients who couldn't afford brand-name Ozempic ($900–$1,100/month) or Wegovy ($1,300–$1,500/month). The pricing difference is significant: most telehealth platforms have offered compounded versions at $100–$450/month.
But the landscape shifted in April 2025 when the FDA removed semaglutide from its drug shortage list — the same shortage designation that had provided the legal authority for large-scale compounding. What that means for patients in 2026, and what you need to evaluate before choosing a compounding route, is what this guide explains.
What "Compounded" Means
Drug compounding is the practice of combining, mixing, or altering ingredients to create a customized medication that isn't commercially available in the needed form. Licensed pharmacists have compounded medications for over a century — for patients who need specific doses, different delivery formats, or allergen-free formulations that manufactured drugs don't provide.
For semaglutide specifically, compounding pharmacies produce injectable vials containing semaglutide as the active ingredient. These preparations are:
- Not FDA-approved. They have not gone through the pre-market safety and efficacy review that Ozempic and Wegovy underwent.
- Legally dispensed under specific conditions. The legal authority to compound semaglutide at scale derived from an FDA drug shortage designation — which changed in 2025 (more on this below).
- Potentially equivalent in active ingredient — but variable in quality, sterility, excipients, and concentration depending on the pharmacy.
Understanding the distinction between FDA-approved brand products and compounded preparations is foundational to evaluating any compounding provider.
The Two Types of Compounding Pharmacies
503A: Traditional Compounding
Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies — state-licensed facilities that compound medications for individual patients with a valid prescription. They operate under state pharmacy board oversight, not direct FDA oversight.
For patients, 503A compounding means:
- A prescription for you specifically is required
- The pharmacy compounds the medication after your prescription is received
- Quality standards are governed by state law and USP standards, not FDA pre-approval
- Sterility testing requirements vary by state
503B: Outsourcing Facilities
Section 503B covers outsourcing facilities — larger-scale compounding operations that voluntarily register with the FDA, submit to FDA inspections, and follow Current Good Manufacturing Practices (CGMP). They can produce drugs without a patient-specific prescription, which is how they supply telehealth platforms at scale.
503B facilities are subject to significantly more rigorous quality standards than 503A pharmacies:
- FDA inspections and registered status
- CGMP requirements
- Sterility testing documentation
- Batch quality control
When evaluating a telehealth provider, asking whether their pharmacy is 503B-registered or 503A provides important context about the quality oversight their product operates under.
The 2025 Shortage List Change: What It Means
From 2022 through early 2025, semaglutide appeared on the FDA's drug shortage list — officially documented scarcity of brand-name Ozempic and Wegovy. This shortage designation provided a legal basis for 503B outsourcing facilities to compound semaglutide at scale, since FDA policy permits compounding of shortage drugs under specific conditions.
In April 2025, the FDA removed semaglutide from the shortage list, stating that supply had caught up with demand. This had direct legal implications:
- 503B facilities lost the shortage-based authority to compound and distribute semaglutide at scale. After a compliance period, continued large-scale 503B compounding of semaglutide was no longer authorized under that exemption.
- 503A pharmacies continue to operate under state pharmacy law and can still compound for individual patient prescriptions, though the FDA has taken the position that compounding copies of approved drugs by 503A pharmacies also raises legal questions.
The practical result for patients in 2026: the market has become more fragmented and legally complex. Some platforms transitioned to compounding under different legal theories; others pivoted to brand-name access programs; others continued operating with ongoing uncertainty about regulatory enforcement.
This doesn't mean compounded semaglutide has disappeared — it means patients need to ask better questions about their provider's specific compounding pathway.
The Semaglutide Acetate Problem
One specific safety issue worth understanding: the salt form of semaglutide.
Approved semaglutide drugs (Ozempic, Wegovy) use semaglutide in its base form. Some compounding pharmacies — particularly those sourcing raw material from non-pharmaceutical-grade suppliers — produced formulations using semaglutide acetate, a different salt form that has not been tested for safety or efficacy in humans.
The FDA issued explicit guidance that semaglutide acetate is not equivalent to pharmaceutical-grade semaglutide and that its use in compounding raises serious safety concerns. When evaluating a compounded semaglutide provider, ask directly: what is the salt form of the semaglutide in your formulation? A legitimate provider should be able to confirm pharmaceutical-grade semaglutide (not semaglutide acetate).
What Compounded Semaglutide Typically Costs
Despite the market changes, compounded semaglutide remains widely available through many telehealth platforms in 2026. Pricing varies by dose and provider model:
| Dose Range | Typical Monthly Cost | Notes |
|---|---|---|
| Starting doses (0.25–0.5mg/week equivalent) | $99–$175/month | Introductory/titration pricing on many platforms |
| Mid-range doses (0.5–1.0mg/week equivalent) | $150–$250/month | Common after first 1–2 months |
| Maintenance doses (1.7–2.4mg/week equivalent) | $250–$450/month | Equivalent dose range to Wegovy maintenance |
| Brand Wegovy (2.4mg/week) | $1,300–$1,500/month | For comparison |
| Brand Ozempic (1.0–2.0mg/week) | $900–$1,100/month | For comparison |
Many platforms bundle the medication with the provider consultation, ongoing monitoring, and messaging — the "per month" price often includes more than just the drug.
How to Evaluate a Compounded Semaglutide Provider
Not all platforms offering compounded semaglutide are equivalent. These questions help distinguish credible providers from those cutting corners.
1. Which pharmacy dispenses your medication? A legitimate platform names its compounding pharmacy and can confirm whether it holds 503A or 503B status. You can verify 503B registration at the FDA's outsourcing facility database. If the platform cannot or will not name its pharmacy, treat that as a significant red flag.
2. What is the active ingredient salt form? Confirm it is semaglutide (not semaglutide acetate). Any legitimate clinical operation should be able to answer this immediately.
3. Is there sterility and potency testing documentation? For injectable medications, sterility testing is non-negotiable. Ask whether batch testing documentation is available. 503B facilities are required to maintain this; 503A facilities should be following USP standards.
4. Is there a real prescriber review? Some platforms offer near-instant "approvals" that border on rubber-stamping. A clinical consultation — even an asynchronous one — should involve a licensed provider actually reviewing your health history, not just an automated intake form checking boxes.
5. What is the dosing format? Legitimate compounded semaglutide typically comes in multi-dose vials with syringes, as opposed to the pre-filled auto-injector pens of brand Ozempic and Wegovy. This is expected and normal — but patients should be prepared for self-administration with a vial and syringe rather than a pen device.
Compounded vs Brand: When Brand Makes Sense
For most patients focused on cost, compounded semaglutide through a legitimate provider delivers clinically meaningful GLP-1 receptor agonist therapy at a fraction of brand-name pricing.
Brand-name products (Ozempic, Wegovy) make sense when:
- Insurance covers the brand medication — if your plan covers Wegovy with a manageable copay, brand is the safer and more straightforward path
- You want the FDA-approved delivery mechanism — Novo Nordisk's pre-filled pens have validated delivery and precision
- You have a strong preference for regulatory certainty — brand products have gone through rigorous FDA review; compounded products have not
Compounded semaglutide makes sense when:
- You're paying out of pocket and brand pricing is not feasible
- Your provider uses a verified 503A or 503B pharmacy with documented quality controls
- You're in the titration phase where lower doses don't yet have a brand equivalent that's cost-effective
Red Flags to Avoid
- Unusually low pricing (under $80/month for any meaningful dose) with no clear explanation — suggests supply chain shortcuts
- Unable to name the dispensing pharmacy
- No prescriber consultation — just an intake form
- Claims of bioequivalence or clinical equivalence to brand drugs — compounded products are not FDA-reviewed and these claims are not substantiated
- Semaglutide acetate as the active ingredient salt form
- No injectable sterility documentation for any product dispensed as an injection
Frequently Asked Questions
Is compounded semaglutide safe?
Compounded semaglutide can be safe when dispensed by a licensed 503B outsourcing facility with verified sterility testing and quality controls — but quality varies widely. The FDA removed semaglutide from its shortage list in April 2025, which changed the legal framework for large-scale compounding. Patients should verify their pharmacy's license, confirm the active ingredient is semaglutide (not semaglutide acetate), and understand that no compounded product undergoes FDA's pre-market approval process.
How much does compounded semaglutide cost in 2026?
Compounded semaglutide through telehealth typically costs $100–$450 per month depending on dose and provider model. Starting doses are often $99–$175/month; maintenance doses typically run $250–$400/month. This compares to approximately $1,300–$1,500/month for brand-name Wegovy.
Is compounded semaglutide still legal in 2026?
The legal status is more complex than it was before April 2025 when the FDA removed semaglutide from its shortage list. 503B large-scale compounding under shortage authority is no longer automatically authorized. 503A patient-specific compounding continues under state pharmacy law. The landscape is evolving and regulatory enforcement is ongoing. Patients should ask their provider specifically about the compounding authority and pharmacy status.
What should I look for in a legitimate compounded semaglutide provider?
Look for: a named, verifiable compounding pharmacy; confirmed use of semaglutide (not semaglutide acetate); documented sterility and potency testing; a real clinical review by a licensed prescriber; and transparent pricing with no hidden fees. Avoid platforms that cannot name their pharmacy or significantly undercut all other market pricing without explanation.
Compare GLP-1 telehealth platforms currently offering compounded semaglutide — including pharmacy transparency ratings and verified pricing — on our provider comparison page.